ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
Rhea-AI Summary
ARS Pharmaceuticals (Nasdaq: SPRY) will present clinical and economic data on neffy® (epinephrine nasal spray) at the AAAAI Annual Scientific Meeting, Feb 27–Mar 2, 2026. Five posters, one HCP case report and two ALK late-breakers cover pharmacokinetics, usability, preference and health‑economic analyses.
Company said neffy 2 mg shows similar exposure to 0.5 mg intramuscular injection, longer shelf life versus autoinjectors, and pharmacoeconomic models indicate increased value when accounting for needle aversion.
Positive
- Pharmacokinetic parity: neffy 2 mg exposure comparable to 0.5 mg IM injection
- Five peer-reviewed posters plus HCP case report and two late-breakers at AAAAI 2026
- Longer shelf life for nasal epinephrine versus autoinjectors, supporting value-based pricing
- Patient preference and adherence analyses suggest >25% increased value when factoring needle aversion
Negative
- None.
News Market Reaction – SPRY
On the day this news was published, SPRY gained 1.33%, reflecting a mild positive market reaction. Argus tracked a trough of -2.3% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $12M to the company's valuation, bringing the market cap to $935.60M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SPRY fell 2.39% while peers were mixed: ATAI +4.25%, RAPP +2.17%, CRMD -1.04%, MRVI -0.96%, XERS -0.57%. The move appears stock-specific rather than sector-driven.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 26 | Phase 2 trial update | Positive | +4.8% | Phase 2 urticaria study where neffy met primary endpoints with rapid symptom control. |
Available tag-specific history shows positive clinical trial news for neffy previously coincided with a positive share reaction.
Recent updates for ARS Pharmaceuticals have centered on neffy’s clinical and commercial expansion. A prior Feb 26, 2024 Phase 2 urticaria study met primary endpoints and drove a 4.79% gain. Since then, broader regulatory and commercialization milestones in multiple regions, plus growing real-world use, have been reported. Today’s AAAAI-focused announcement adds further pharmacokinetic, usability and preference data, extending the clinical narrative beyond efficacy into health-economics and patient experience.
Historical Comparison
Clinical trial–type updates for neffy have historically produced an average move of about 4.79%, suggesting prior market sensitivity to similar data disclosures.
Clinical communications have progressed from Phase 2 symptom-control efficacy data toward broader pharmacokinetic, usability, preference and health-economic evidence for neffy.
Market Pulse Summary
This announcement expands the clinical and real-world narrative around neffy, adding pharmacokinetic, usability, preference and health-economic data across five company posters, partner late-breakers and an HCP case report. Historically, a neffy Phase 2 urticaria update on Feb 26, 2024 prompted a 4.79% move, indicating market attention to clinical milestones. Investors may track future trial readouts, regulatory actions and real-world outcomes to contextualize these AAAAI presentations.
Key Terms
epinephrine nasal spray medical
intramuscular injection medical
pharmacokinetics medical
pharmacodynamics medical
discrete choice experiment technical
anaphylaxis medical
late-breaking technical
AI-generated analysis. Not financial advice.
-Five poster presentations highlight clinical advancement of neffy, real-world usability and advantages of needle-free epinephrine delivery
-Longer shelf life of nasal epinephrine compared with epinephrine auto-injectors translates into a more affordable, value-based price
-When factoring in patients’ dislike of needle-based administration, the value of a nasal option increased by more than
SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, announced today that five poster presentations, one healthcare professional (HCP) case report, plus two late breakers from partners at ALK-Abelló A/S (ALK) centered on neffy, will be featured at the 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting, February 27 to March 2, 2026 in Philadelphia, Pennsylvania. The posters highlight health-economic analyses, patient preference research, usability and pharmacokinetic comparisons evaluating neffy relative to injectable epinephrine products.
“We are pleased to share with the broader allergy community at AAAAI a series of new clinical insights showcasing the similarity of neffy 2 mg in exposure as compared to 0.5 mg intramuscular injection, as well as positive pharmacoeconomic data that indicates neffy may be cost effective and preferred by patients over injection products,” said Sarina Tanimoto, MD, PhD, Co-Founder and Chief Medical Officer of ARS Pharma. “These studies reinforce our commitment to delivering an intuitive, affordable, and reliable nasal spray that patients and caregivers can trust in emergency situations.”
The complete list of presentations and meeting activities is below. Abstracts can be viewed at annualmeeting.aaaai.org. Attendees are encouraged to visit the ARS Pharma booth #737, view the poster presentations at the Convention Center, Level 2, Hall E, and attend a Non-CME Problem Based Learning Presentation: Reimagining Epinephrine Administration with Epinephrine Nasal Spray, to learn more about neffy.
| ARS Poster Presentations – February 28, 2026 | ||
| Poster Presentation #1 | ||
| Time: | 9:45 a.m. - 10:45 a.m. EST | |
| Title: | The Expected Societal Value of Nasal Epinephrine Generated from Needle Aversion | |
| Authors: | Niraj C. Patel, MD, Matthew J. Greenhawt, MD, Shahzad Mustafa, MD, Aikanterini Anagnostou, MD, PhD, Eric Karas, Sarina Tanimoto, MD, PhD, Stella Arndorfer, Melanie Whittington, Richard Xie | |
| Poster ID: | 485 | |
| Poster Presentation #2 | ||
| Time: | 9:45 a.m. - 10:45 a.m. EST | |
| Title: | Pharmacokinetics and Pharmacodynamics of Epinephrine Nasal Spray and Intramuscular Epinephrine 0.5 mg Injection | |
| Authors: | Jonathan M. Spergel, MD, David B. K. Golden, MDCM, Michael S. Blaiss, MD, Richard Lowenthal, MSc, Sarina Tanimoto, MD, PhD | |
| Poster ID: | 370 | |
| Poster Presentation #3 | ||
| Time: | 9:45 a.m. - 10:45 a.m. EST | |
| Title: | Treatment Preference Related to Nasal Epinephrine versus Autoinjector in Food Allergic Adult and Adolescent Patients | |
| Authors: | Theresa Bingemann, MD, Matthew J. Greenhawt, MD, Warner Carr, MD, Jay A. Lieberman, MD, Aikaterini Anagnostou, MD, PhD, Joel Brooks, DO, Niraj C. Patel, MD, Shahzad Mustafa, MD, Rebekah Hall, Siu Hing Lo, Sarina Tanimoto, MD, PhD, Richard Xie | |
| Poster ID: | 376 | |
| Poster Presentation #4 | ||
| Time: | 9:45 a.m. - 10:45 a.m. EST | |
| Title: | Relative Importance of Characteristics of Epinephrine Treatments for Severe Food Allergic Reactions – A Discrete Choice Experiment with Patients | |
| Authors: | Aikaterini Anagnostou, MD, PhD, Matthew J. Greenhawt, MD, Jay A. Lieberman, MD, Joel Brooks, DO, Rebekah Hall, Siu Hing Lo, Eric Karas, Sarina Tanimoto, MD, PhD, Richard Xie | |
| Poster ID: | 377 | |
| Poster Presentation #5 | ||
| Time: | 9:45 a.m. - 10:45 a.m. EST | |
| Title: | Treatment Adherence Related to Nasal Epinephrine versus Autoinjector in Food Allergic Adult and Adolescent Patients | |
| Authors: | Warner Carr, MD, Jay A. Lieberman, MD, Theresa Bingemann, MD, Matthew J. Greenhawt, MD, Aikaterini Anagnostou, MD, PhD, Joel Brooks, DO, Niraj C. Patel, MD, Shahzad Mustafa, MD, Rebekah Hall, Siu Hing Lo, Sarina Tanimoto, MD, PhD, Richard Xie | |
| Poster ID: | 417 | |
| HCP Case Report Featuring Intranasal Epinephrine – March 1, 2026 | ||
| Time: | 9:45 a.m. -10:45 a.m. EST | |
| Title: | Effectiveness of Intranasal Epinephrine in Routine Allergy Practice | |
| Authors: | Haley Overstreet, MD, Stacy Silvers, MD, Hary Katz, MD, Jake Rosenblum, DO, Christina Long, MPAS, PA-C, Michael Rupp, MD, Kristina Kwak, MD, Krista Todoric, MD, Paul Ogershok, MD, Ali Doroudchi, MD | |
| Poster ID: | L68 | |
| ALK Partner Poster Presentations – March 1, 2026 | ||
| Late-Breaking (LB) Poster Session II: | ||
| Time: | 9:45 am - 10:45 am EST | |
| Title: | Making Epinephrine More Portable – Insights into Device Carriage and Preference | |
| Poster ID: | L70 | |
| Time: | 9:45 am - 10:45 am EST | |
| Title: | Expanding Patient Choice in Anaphylaxis Management - User Preference Between Epinephrine Autoinjectors and Nasal Delivery New Submission | |
| Poster ID: | L69 | |
| Onsite Event – February 26, 2026 | ||
| Time: | 6:30 p.m. – 8:30 p.m. EST | |
| Title: | Non-CME PBL Presentation: Reimagining Epinephrine Administration with Epinephrine Nasal Spray | |
| Location: | Philadelphia Marriott Downtown | |
| Marriott Level 5 | ||
| Grand Ballroom Salon H | ||
About neffy®
neffy is a nasal spray used for emergency treatment of allergic reactions including anaphylaxis, in adults and children aged 4 years and older who weigh 33 lbs. or greater.
INDICATION AND IMPORTANT SAFETY INFORMATION FOR neffy (epinephrine nasal spray)
INDICATION
neffy is indicated for emergency treatment of type I allergic reactions, including anaphylaxis, in adult and pediatric patients aged 4 years and older who weigh 33 lbs. or greater.
IMPORTANT SAFETY INFORMATION
neffy contains epinephrine, a medicine used to treat allergic emergencies (anaphylaxis). Anaphylaxis can be life-threatening, can happen in minutes, and can be caused by stinging and biting insects, allergy injections, foods, medicines, exercise, or other unknown causes.
Always carry two neffy nasal sprays with you because you may not know when anaphylaxis may happen and because you may need a second dose of neffy if symptoms continue or come back.
Each neffy contains a single dose of epinephrine. neffy is for use in the nose only.
Use neffy right away, as soon as you notice symptoms of an allergic reaction. If symptoms continue or get worse after the first dose of neffy, a second dose is needed. If needed, administer a second dose using a new neffy in the same nostril starting 5 minutes after the first dose. Get emergency medical help for further treatment of the allergic emergency (anaphylaxis), if needed after using neffy.
Tell your healthcare provider if you have underlying structural or anatomical nasal conditions, about all the medicines you take, and about all your medical conditions, especially if you have heart problems, kidney problems, low potassium in your blood, Parkinson's disease, thyroid problems, high blood pressure, diabetes, are pregnant or plan to become pregnant, or plan to breastfeed.
Tell your healthcare provider if you take or use other nasal sprays or water pills (diuretics) or if you take medicines to treat depression, abnormal heart beats, Parkinson's disease, heart disease, thyroid disease, medicines used in labor, and medicines to treat allergies. neffy and other medications may affect each other, causing side effects. neffy may affect the way other medicines work, and other medicines may affect how neffy works.
neffy may cause serious side effects. If you have certain medical conditions or take certain medicines, your condition may get worse, or you may have more or longer lasting side effects when you use neffy.
Common side effects of neffy include: nasal discomfort, headache, throat irritation, chest and nasal congestion, feeling overly excited, nervous or anxious, nose bleed, nose pain, sneezing, runny nose, dry nose or throat, tingling sensation, including in the nose, feeling tired, dizziness, nausea, and vomiting.
Tell your healthcare provider if you have any side effects that bother you or that do not go away after using neffy.
These are not all of the possible side effects of neffy. Call your healthcare provider for medical advice about side effects. To report side effects, contact ARS Pharmaceuticals Operations, Inc. at 1-877-MY-NEFFY (877-696-3339) or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see the full Prescribing Information and Patient Information for neffy.
About Type I Allergic Reactions Including Anaphylaxis
Type I allergic reactions are serious and potentially life-threatening events that can occur within minutes of exposure to an allergen and require immediate treatment with epinephrine, the only FDA-approved medication for these reactions. While epinephrine auto-injectors have been shown to be highly effective, there are well published limitations that result in many patients and caregivers delaying or not administering treatment in an emergency situation. These limitations include fear of the needle, lack of portability, needle-related safety concerns, lack of reliability, and complexity of the devices. There are approximately 40 million people in the United States who experience Type I allergic reactions. Of this group, over the last three years, approximately 20 million people have been diagnosed and treated for severe Type I allergic reactions that may lead to anaphylaxis, but (in 2023, for example) only 3.2 million filled their active epinephrine auto-injector prescription, and of those, only half consistently carry their prescribed auto-injector. Even if patients or caregivers carry an auto-injector, more than half either delay or do not administer the device when needed in an emergency.
About ARS Pharmaceuticals, Inc.
ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy® (trade name EURneffy® in the EU and 优敏速® in China), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients 4 years of age and older who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit www.ars-pharma.com.
Forward-Looking Statements
Statements in this press release that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to: the patient benefits and effectiveness of neffy, including its needle-free design, extended shelf life, value, and affordability; evaluations and judgments regarding the similarity of neffy 2 mg in exposure as compared to 0.5 mg intramuscular injection and that neffy may be more cost-effective and preferred by patients over injection products; and other statements that are not historical fact. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “anticipate,” “believe,” “can,” “could,” “expect,” “if,” “may,” “on track to/for,” “potential,” “plan,” “will,” “would,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon ARS Pharmaceuticals’ current expectations and involve assumptions that may never materialize or may prove to be incorrect.
Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: potential safety and other complications from neffy; the ability to obtain and maintain regulatory approval for neffy in its currently approved indications; the scope, progress and expansion of developing and commercializing neffy; the scope, progress and expansion of developing our intranasal epinephrine technology; clinical trial results; the potential for governments and payors to delay, limit or deny coverage for neffy; the size and growth of the market for neffy and the rate and degree of market acceptance thereof vis-à-vis intramuscular injectable products; ARS Pharma’s ability to protect its intellectual property position; and the impact of government laws, regulations and policies. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption “Risk Factors” in ARS Pharma’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the SEC on November 10, 2025. This document can also be accessed on ARS Pharma’s website at www.ars-pharma.com by clicking on the link “Financials & Filings” under the “Investors & Media” tab.
The forward-looking statements included in this press release are made only as of the date hereof. ARS Pharma assumes no obligation and does not intend to update these forward-looking statements, except as required by law. For more information, visit www.ars-pharma.com, and follow us on LinkedIn and X.
ARS Investor Contact:
Justin Chakma
ARS Pharmaceuticals
justinc@ars-pharma.com
ARS Media Contact:
Christy Curran
Sam Brown Inc.
615.414.8668
christycurran@sambrown.com
FAQ
What clinical data will ARS Pharmaceuticals (SPRY) present about neffy at AAAAI 2026?
Does neffy (SPRY) match injectable epinephrine exposure in the pharmacokinetic data?
How does neffy’s shelf life affect pricing and value for SPRY investors?
What evidence did ARS (SPRY) cite regarding patient preference for neffy over autoinjectors?
Where and when can investors see ARS (SPRY) presentations on neffy at AAAAI 2026?
